A Phase I Trial of HS-10241 in Solid Tumors

Solid Tumors Clinical Trial

Official title:

First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02759640
• Other study ID #: HS-10241-001
• Status: Completed
• Phase: Phase 1
• Start date: September 2016
• Est. completion date: May 2018

Study information

• Verified date: February 2019
• Source: Atridia Pty Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.

Description:

Recently, c-Met has become an important target of intensive research in search of specific inhibitors as potential new therapies for cancers driven by c-Met activation. HS-10241 is a potent and selective small molecule c-Met kinase inhibitor for both enzyme and c-Met phosphorylation in the cell. Consistent with its potent enzyme and cell activity, HS-10241 was found to inhibit cell growth in vitro against tumors with c-Met gene amplification or c-Met overexpression. On the basis of these findings, the current trial will be conducted in participants with advanced solid tumors for whom standard treatment is not currently available.

This study consists of 2 phases. In the dose-escalation phase, up to 5 dose levels of HS-10241 (100 mg/day, 200 mg/day, 340 mg/day, 500 mg/day, and 700 mg/day) will be investigated with a sequential "3+3" design (3 or 6 participants in every dose level). Participants will have a single-dose pharmacokinetic (PK) run-in period (7 days). Following the first dose, participants will enter a 1 week treatment-free period to evaluate safety and single-dose PK. If no dose-limiting toxicities (DLTs) are observed during the 1-week period, HS-10241 administration will resume at the same dose level.

In the expansion phase, up to 12 additional participants will be enrolled at the MTD. Anti-tumor effects will be assessed every 2 cycles (4 weeks=1 cycle) by using RECIST version 1.1 criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: May 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. At least 18 years of age

2. Ability to understand the purposes and risks of the trial and his/her informed consent using the Human Research Ethics Committee (HREC) approved informed consent form (ICF).

3. Histologically or cytologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused.

4. Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia)

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Life expectancy of at least 3 months

7. Acceptable liver function defined below:

• Total bilirubin = 2 times upper limit of normal range (ULN)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 times ULN; however, =5 times ULN in a subject who has liver metastases

8. Acceptable renal function defined below:

• Serum creatinine =1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) =60 mL/minutes

9. Acceptable coagulation status defined below:

• Prothrombin time <1.5 times ULN

• Partial thrombin time <1.5 times ULN

10. Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:

• Absolute neutrophil count (ANC) =1500/µL

• Platelet count =100000/µL

• Hemoglobin =9.0 g/dL

11. No clinically significant abnormalities in urinalysis

12. All participants must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device) with their partner from entry into the trial through 6 months after the last dose.

Exclusion Criteria:

1. Hematologic malignancies

2. Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease

3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

4. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery

5. Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris

6. Seizure disorders requiring anticonvulsant therapy

7. Taking a medication that prolongs QT interval and has a risk of Torsade de Pointes, or a history of long QT syndrome

8. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product

9. Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry. Ongoing androgen deprivation therapy or bisphosphonates are allowed.

10. Participation in an investigational drug or device trial within 4 weeks prior to the trial entry

11. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

12. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of trial entry)

13. History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis;

14. Subject is pregnant (positive serum beta human chorionic gonadotropin [ß-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment

15. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial

16. History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation

17. Unwillingness or inability to comply with the trial protocol for any reason

18. Legal incapacity or limited legal capacity

19. Known drug abuse or alcohol abuse

20. Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9. Patients are eligible if these medications can be stopped or substituted within the screening period.

Related Conditions & MeSH terms

• Neoplasm
• Neoplasms
• Solid Tumors

Intervention

Drug:
• HS-10241
HS-10241 is administered orally starting at 100 mg/day.

Locations

Country	Name	City	State
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Liverpool	Liverpool	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Atridia Pty Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	MTD is defined as the maximum dose level at which no more than 1 out of 3 participants experience a DLT within the first 4 weeks of multiple dosing.	4 weeks
Secondary	Number of participants with treatment-emergent adverse events (TEAEs)		24 months
Secondary	Peak plasma concentration (Cmax)		4 weeks
Secondary	Area under the plasma concentration-time curve (AUC)		4 weeks
Secondary	T1/2 (half-life)		4 weeks
Secondary	Objective response rate (ORR)		24 months
Secondary	Time to reach maximum plasma concentration (Tmax)		4 weeks
Secondary	Clearance (CL)		4 weeks
Secondary	Volume of distribution at steady state (Vss)		4 weeks